We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. An investigational oral drug lowered lipoprotein(a) ...

Please provide your email address to receive an email when new articles are posted on . Muvalaplin, the first oral therapy developed to lower lipoprotein(a), did so in a phase 1 study. An extended ...

LP-310 shows significant improvements in pain and inflammation for oral lichen planus, with favorable safety results in Phase 2a trial. Lipella Pharmaceuticals has announced promising results from its ...

CHICAGO, IL—Two new drugs targeting lipoprotein(a)—one a small interfering RNA (siRNA), the other an oral agent that prevents its formation—both showed positive results in early phase II studies, with ...

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine ...

SAN DIEGO, March 2, 2025 /PRNewswire/ — Longbio Pharma (Suzhou) Co., Ltd. (referred to as “Longbio”), a leading biotech company dedicated to developing innovative biologic treatments for allergy, ...

Japanese patient cohort enrollment is completed ahead of schedule at multiple clinical sites including the National Cancer Center in Tokyo The incidence rate of never-smokers with non-small cell lung ...

Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI)-driven oncology company leveraging its proprietary RADR® platform to accelerate targeted cancer therapies, today announced ...

Pfizer (PFE) and BioNTech (BNTX) announced topline results from an ongoing Phase 3 clinical trial cohort evaluating the safety, tolerability, and immunogenicity of a 30-microgram dose of the ...

Okay. Thank you, everyone, for joining us today for our LP-184 clinical trial results webinar. We'll be talking in depth today with some of our Lantern's team and also with our collaborator and ...

Lipella Pharmaceuticals Inc. announced positive topline results from the second cohort of its Phase 2a clinical study of LP-310, a liposomal-tacrolimus oral rinse aimed at treating oral lichen planus ...